Progress in local treatment of liver metastasis of colorectal cancer

doi:10.3877/cma.j.issn.1674-0785.2019.07.012

Abstract

Abstract:

Colorectal cancer is a common gastrointestinal malignancy, which is prone to liver metastasis. Surgical resection of liver metastases is one of the important treatment methods. With the progress of clinical diagnosis and treatment technology, interventional therapy, radiotherapy, and other methods have become important options of treatment for colorectal cancer liver metastasis. This article will review the progress in local treatment of liver metastasis of colorectal cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Ablation, Chemoembolization, therapeutic, Radiotherapy

Cong Jing, Yongjun Ren, Jin Deng, Xuli Min, Hao Xu, Zhiliang Chen. Progress in local treatment of liver metastasis of colorectal cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(07): 540-543.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2019.07.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2019/V13/I07/540

References 35

[1]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136: E359-E386.
[2]	Brenner H, Kloor M, Pox CP. Colorectal cancer [J]. Lancet, 2014, 383(9927): 1490-1502.
[3]	Levy J, Zuckerman J, Garfinkle R, et al. Hepatic intra-arterial therapies for unresectable and chemo-refractory colorectal cancer liver metastases: systematic review and pooled analysis [J]. HPB, 2017, 19(1): S53．
[4]	Tomlinson JS, Jarnagin WR, DeMatteo RP. Actual 10-year survival after resection of colorectal liver metastases defines cure [J]. J Clin Oncol, 2007, 25(29): 4575-4580.
[5]	House MG, Kemeny NE, Gönen M. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer [J]. Ann Surg, 2011, 254(6): 851-856.
[6]	Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from color ectal cancers: an update [J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 570-580.
[7]	Norén A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases, a nationwide study [J]. Eur J Cancer, 2016, 53: 105-114.
[8]	Norén A, Sandstrom P, Gunnarsdottir K, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastase in Sweden [J]. Scand J Surg, 2018, 4(107): 294-301.
[9]	Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status [J]. World J Radiol, 2010, 2(11): 417-424.
[10]	Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013 [J]. Eur Radiol, 2015, 25(12): 3438-3454.
[11]	Cheng JQ, Weng M, Zhang Y, et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a metaanalysis [J]. PLoS One, 2012, 7(9): e45493.
[12]	Babawale SN, Jensen TM, Frkjr JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: a retrospective study [J]. World J Gastrointest Surg, 2015, 7(3): 33-38．
[13]	Sucandy I, Cheek S, Golas BJ, et al. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors [J]. HPB( Oxford), 2016, 18(9): 756-763．
[14]	Lee BC, Lee HG, Park IJ, et al. The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer [J]. Medicine (Baltimore), 2016, 95( 39): e4999．
[15]	Zarour LR, Anand S, Billingsley KG, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions [J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2): 163-173.
[16]	Stang A, Oldhafer KJ, Weilert H, et al. Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal [J]. BMC Cancer, 2014, 14: 500．
[17]	Tombesi P, Di VF, Sartori S. Resection vs thermal ablation of small hepatocellular carcinoma: what′s the first choice? [J]. World J Radiol, 2013, 5(1): 1-4.
[18]	Shono Y, Tabuse K, Tsuji T, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor [J]. Gan To Kagaku Ryoho, 2002, 29(6): 856-859.
[19]	Grundmann RT, Hermanek P, Merkel S, et al. Diagnosis and treatmen t of colorectal liver metastases workflow [J]. Zentralbl Chir, 2008, 133(3): 267-284.
[20]	Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases [J]. Ann Surg Oncol, 2014, 21(13): 4278-4283.
[21]	Song KD. Percutaneous cryoablation for hepatocellular carcinoma [J]. Clin Mol Hepatol, 2016, 22(4): 509-515.．
[22]	Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma [J]. Hepatology, 2015, 61(5): 1579-1590.
[23]	Rong G, Bai W, Dong Z, et al. Longterm outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria [J]. PloS One, 2015, 10(4): e0123065．
[24]	Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population [J]. Cardiovasc Intervent Radiol, 2014, 37(1): 154-164．
[25]	Breedis C, Young G. The blood supply of neoplasms in the liver [J]. Am J Pathol, 1954, 30(5): 969-977.
[26]	含笑. 肝转移癌TACE疗效评价及影响因素分析[D].合肥:安徽医科大学, 2013.
[27]	Li C, Gu Y, Zhao M, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer [J]. Cancer Chemother Pharmacol, 2014, 74(5): 1079-1087.
[28]	Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer [J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553.
[29]	Hoyer M, Roed H, Traberg Hansen A, et al. PhaseⅡ study on stereotactic body radiotherapy of colorectal metastases [J]. Acta Oncol, 2006, 45(7): 823-830.
[30]	van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases [J]. Br J Surg, 2010, 97(3): 377-382.
[31]	Ren ZG, Zhao JD, Gu K, et al．Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study [J]. Int J Radiat Oncol Biol Phys, 2011, 79(2): 496-502．
[32]	van Hazel GA, Heinemann V, Sharma NK, et al．SIRFLOX: randomized phase Ⅲ trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2016, 34(15): 1723-1731．
[33]	周定中，曹苏娟，李庆, 等. TACE联合DC-CIK生物治疗结直肠癌肝转移的临床应用 [J].临床放射学杂志, 2016, 35(5): 771-774.
[34]	翟霏霏. 树突状细胞疫苗联合射频消融术治疗结直肠癌转移临床疗效[D].合肥: 安徽医科大学, 2016.
[35]	吴倩，张文涛，沈健美. 高能聚焦超声刀联合化疗治疗不能手术的结直肠癌肝转移的近期疗效 [J]. 现代肿瘤医学, 2016, 24(17): 2755-2758.

Please choose a citation manager

Content to export